BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//SenzaGen - ECPv6.18.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SenzaGen
X-ORIGINAL-URL:https://senzagen.com
X-WR-CALDESC:Events for SenzaGen
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Stockholm
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20251002T140000
DTEND;TZID=Europe/Stockholm:20251002T180000
DTSTAMP:20250929T062850Z
CREATED:20250828T192933Z
LAST-MODIFIED:20250929T062850Z
UID:35473-1759413600-1759428000@senzagen.com
SUMMARY:Medicon Valley MedTech Network meeting
DESCRIPTION:Understanding Biological Evaluation of Medical Devices\nJoin the next Medicon Valley MedTech Network meeting in Lund to gain insights into the general principles of biological safety evaluation\, what to consider\, why it matters\, and how upcoming changes to ISO 10993-1 may affect the process.  \nSenzaGen’s in vitro skin sensitization expert\, Dr Andy Forreryd\, will be joined by other industry experts to share experiences and discuss the challenges faced in the biological evaluation of medical devices. \nRedefining Biocompatibility Testing: The Role of In Vitro Models in Product Development and regulatory submissions Speaker: Andy Forreryd\, PhD\, Scientific Liaison Manager\, SenzaGen \nRead the full agenda and sign up here \n  \n \n  \n  \n 
URL:https://senzagen.com/event/medicon-valley-medtech-network-meeting/
LOCATION:Lund\, Sweden
CATEGORIES:Seminar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2025/08/medtech-network-banner-WEB_Final-e1756409677112.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20251008T160000
DTEND;TZID=Europe/Stockholm:20251008T170000
DTSTAMP:20250923T091749Z
CREATED:20250822T075505Z
LAST-MODIFIED:20250923T091749Z
UID:35388-1759939200-1759942800@senzagen.com
SUMMARY:Webinar: In vitro skin sensitization potency assessment
DESCRIPTION:Using GARD® to derive PoDs and safe dose levels for skin sensitizers\nChemicals | Natural Extracts | Complex Mixtures \nJoin our upcoming webinar to explore how GARD® enables the derivation of Points of Departure (PoDs) for Quantitative Risk Assessment (QRA) and helps establish safe dose levels for identified sensitizers. \nWith broad applicability to complex mixtures and new raw materials with challenging properties\, GARD® offers a powerful non-animal solution in skin sensitization potency assessment. \nTypical challenges you may face: \n\nYou have a new ingredient that is a sensitizer. At what dose level is it safe to use?\nYou are planning for confirmatory human patch testing (HRIPT). How can you obtain a NESIL value?\nYou are performing a Risk Assessment for a new active ingredient in a complex formulation. How can you get a PoD/NESIL for QRA?\n\nAs practical examples\, we will showcase scientific collaborations with Unilever\, BIC\, Takasago\, dōTERRA\, International Flavors & Fragrances (IFF) and the Research Institute for Fragrance Materials (RIFM). \n \nKey topics\n\nIntroduction to New Approach Methodologies (NAMs) for skin sensitization potency assessment.\nHow to overcome common challenges in deriving PoDs and establishing safe dose levels for skin sensitizers.\nCase studies on Fragrances\, Essential Oils\, Botanical Extracts\, and Complex Mixtures.\n\nThe webinar will last around 30 minutes\, followed by a live Q&A. If you cannot attend the live event\, make sure to register to get access to the recording. \nSpeaker\n \nAndy Forreryd\, PhD\nScientific Liaison Manager @ SenzaGen \n\nCo-developer of the GARD®skin assay (OECD TG 442E).\nMember of the ISO/TC 194/WG 8 on irritation and sensitization.\nMember of OECD expert group on respiratory sensitization.
URL:https://senzagen.com/event/webinar-skin-sensitization-potency-assessment/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2025/01/Lime-UNIVERSAL-webinar.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251015
DTEND;VALUE=DATE:20251019
DTSTAMP:20250828T195046Z
CREATED:20250828T135526Z
LAST-MODIFIED:20250828T195046Z
UID:35428-1760486400-1760831999@senzagen.com
SUMMARY:ICT/IUTOX 2025
DESCRIPTION:ICT 2025 / IUTOX 17th International Congress of Toxicology\n📍 Beijing\, China | 🗓 October 15–18\, 2025\nMeet us at this year’s ICT/IUTOX conference in Beijing\, where SenzaGen’s scientific team will share new insights on quantitative skin sensitization potency assessment and present results from the pre-validation study of GARD®skin Medical Device. \nWhat to connect with us while you are there? \n \nPosters\n🎫  #645 | Quantitative skin sensitization potency assessment\nAdvancing in vitro skin sensitization potency assessment using GARDskin Dose-Response \n🎫 #649 | Application for medical devices\nPre-validation results from GARDskin for Medical Devices: In vitro sensitization testing of medical device extracts for implementation in ISO 10993-10
URL:https://senzagen.com/event/ict-iutox-2025/
LOCATION:Beijing\, China
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2025/08/ICT-banner-e1756389255388.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251021
DTEND;VALUE=DATE:20251024
DTSTAMP:20250828T193940Z
CREATED:20250828T140923Z
LAST-MODIFIED:20250828T193940Z
UID:35446-1761004800-1761263999@senzagen.com
SUMMARY:ASCCT 2025
DESCRIPTION:ASCCT 14th Annual Meeting\n📍 Gaithersburg\, USA | 🗓 October 21–23\, 2025\nMeet us at this year’s ASCCT annual meeting in Gaithersburg\, where SenzaGen’s scientific team will share new insights on quantitative skin sensitization potency assessment and present results from the pre-validation study of GARD®skin Medical Device. \nWhat to connect with us while you are there? \n \nMore information coming soon!
URL:https://senzagen.com/event/ascct-2025/
LOCATION:Gaithersburg\, Md\, USA
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2025/08/25133-RAD-ASCCT-Annual-Meeting-Graphics_IIVS-Update-1584x396-1-e1756392285881.jpg
END:VEVENT
END:VCALENDAR